semaglutide diabetes research GLP-1 receptor agonists can reduce the risk of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or obesity Diabetes Drug Could Help Reduce

That is basically a 27 BMI (body mass index) and a weight-related comorbidity, or a 30 BMI and above. Comorbidities include type 2 diabetes, hypertension, dyslipidemia, heart disease, osteoarthritis, obstructive sleep apnea, kidney disease and non-alcoholic fatty liver disease

In addition, this medication also suppresses gastric acid secretion and promotes satiety, resulting in appetite reduction

Ages 60 and older, a history of kidney disease or kidney failure, and individuals using medications such as blood thinners, immunosuppressants or corticosteroids, may increase the risk of developing side effects including joint pain

How quickly will I see results

The key difference is what the FDA says you can use it for